NYSE:NNVC
NANOVIRICIDES, INC.
A clinical-stage biotech company pioneering next-generation antiviral therapies for emerging viral pathogens.
Key Metrics
Investment Thesis
Bull Case
Investors may view the stock as a high-risk venture play on breakthrough antiviral technology with potential for transformative market impact upon regulatory approval. The broad-spectrum nature of the pipeline offers a defensive hedge against future pandemics or emerging viral threats not covered by current vaccines. Early-stage biotech exposure provides significant upside potential if clinical milestones are met and partnerships are secured.
Bear Case
The company operates at a deep loss with no commercial revenue, creating extreme financial vulnerability to cash flow interruptions or failed clinical trials. Shareholders face dilution from the $5.3M in financing inflows required to fund operations against $8.5M in cash outflows and a massive retained earnings deficit of $148.8M. High volatility is expected given the binary nature of biotech outcomes with no guaranteed path to profitability.
About NANOVIRICIDES, INC.
Nanoviricides Inc. is a biotechnology firm focused on developing novel antiviral therapeutics and vaccines to address emerging viral threats. The company leverages proprietary technologies to create broad-spectrum solutions against viruses that evade traditional treatments, targeting markets in infectious disease prevention and treatment globally.
Analysis
Management Discussion
The company reported a net loss of $9.5M in 2025, reflecting substantial investments in research and development totaling $5.5M alongside significant depreciation and amortization costs. Despite generating positive cash flow from financing activities of $5.3M, the firm consumed approximately $8.5M in operating cash flow, resulting in a net decrease in cash reserves over the reporting period.
Industry Overview
The antiviral therapeutics sector is rapidly evolving as global health priorities shift towards preparing for pandemics and treating resistant viral strains. Biotechnology firms are increasingly utilizing AI-driven discovery and broad-spectrum approaches to overcome limitations of narrow-targeted treatments. Regulatory pathways continue to adapt to support urgent development of countermeasures for high-consequence pathogens.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $8.9M | $8.5M | $9.6M |
| Operating Income | $-8.9M | $-8.5M | $-9.6M |
| R&D | $6.4M | $5.4M | $5.5M |
| G&A | $2.6M | $3.1M | $4.0M |
| Stock-Based Comp | $44.0K | $563 | — |
| Depreciation | $739.3K | $750.7K | $735.5K |
| Amortization | $8.3K | $8.3K | $8.3K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $938 | — | — |
| Pre-Tax Income | $-8.9M | $-8.5M | $-9.6M |
| Income Tax | $-354.9K | $-222.0K | $-124.7K |
| Continuing Ops | $-8.6M | $-8.3M | $-9.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.6M | $-8.3M | $-9.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.6M | $-8.3M | $-9.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $8.4M | $5.0M | $1.7M |
| Cash & Equivalents | $8.1M | $4.8M | $1.6M |
| Other Current Assets | $295.5K | $172.7K | $112.1K |
| Long-Term Assets | $8.5M | $7.9M | $7.2M |
| PP&E (Net) | $8.1M | $7.5M | $6.8M |
| Intangibles | $333.6K | $325.3K | $317.0K |
| Other LT Assets | $14.4K | $14.6K | $2.4K |
| Total Assets | $16.9M | $12.8M | $8.8M |
| Current Liabilities | $534.2K | $1.4M | $1.3M |
| Other Current Liab | $390.5K | $1.1M | $1.3M |
| Long-Term Liabilities | $1.5M | $0 | $-6.5K |
| Total Liabilities | $2.0M | $1.4M | $1.3M |
| Shareholders' Equity | $14.9M | $11.5M | $7.5M |
| Paid-In Capital | $145.9M | $150.8M | $156.4M |
| Retained Earnings | $-131.1M | $-139.4M | $-148.8M |
| Total L&E | $16.9M | $12.8M | $8.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-8.6M | $-8.3M | $-9.5M |
| Non-Cash Adjustments | $2.8M | $1.2M | $1.1M |
| Working Capital Changes | $133.6K | $751.8K | $-125.0K |
| Cash from Operations | $-5.7M | $-6.3M | $-8.5M |
| Capital Expenditures | $151.7K | $156.6K | $57.0K |
| Cash from Investing | $-151.7K | $-156.6K | $-57.0K |
| Cash from Financing | $-94.8K | $3.1M | $5.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-5.9M | $-3.4M | $-3.2M |
| Beginning Cash | $14.1M | $8.1M | $4.8M |
| Ending Cash | $8.1M | $4.8M | $1.6M |
Frequently Asked Questions
How does NANOVIRICIDES, INC. make money?
The company's operations are primarily centered on drug discovery and development of novel antiviral candidates, with R&D activities focusing on broad-spectrum efficacy against diverse viral families. All financial data indicates a pre-revenue stage where costs are driven by research, clinical trials, and manufacturing scale-up preparations rather than commercial sales.
What are the main risks for NNVC?
Significant ongoing net losses and cash burn rate with no current revenue stream to sustain operations long-term. High dependence on successful clinical trial outcomes which carry inherent regulatory and scientific failure risks. Dilution risk for shareholders as the company may need to raise additional capital through equity offerings or debt financing to fund development.
What is NNVC's competitive advantage?
Proprietary technology platforms that enable the rapid development of broad-spectrum antivirals capable of targeting multiple viral strains simultaneously. Strong intellectual property portfolio protecting novel mechanisms of action distinct from existing market standards. Strategic partnerships or licensing potential to accelerate clinical progress and reduce capital burden.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.